Postdoc
PhD Prasanna Vasudevan Iyengar
Research:
I am trained as a Molecular biologist with particular interests in uncovering how dysregulation of molecules causes cancer progression. Specifically, I study post-translational modifications of proteins such as ubiquitylation, phosphorylation and methylation, that lead to perturbation of key intracellular signaling pathways like TGF-b, HGF, MAPK and Akt. Apart from proteins, with keen interests, I supervise projects that aim to uncover important non-coding RNAs that lurk beneath the genomic surface.
Curriculum Vitae:
I am originally from India, I performed my doctoral thesis at the Department of Biological Sciences, Tokyo Institute of Technology, Japan, under the supervision of Profs. Shigehisa Hirose and Nobuhiro Nakamura. Here, I was part of a screen to characterize a sub-family of E3 ubiquitin ligases that were involved in mammalian spermatogenesis. To further my understanding of these ubiquitin-modifying enzymes and to figure out ‘how and why’ dysregulation of these enzymes lead to cancer, I joined the laboratory of Dr. Pieter Eichhorn, Cancer Science Institute of Singapore, National University of Singapore. From 2017, under the mentorship of Prof. Peter ten Dijke, I am focusing my efforts on developing therapeutic strategies and novel biomarkers to target aberrantly expressed ubiquitin-modifying enzymes.
Awards:
Japanese government scholarship (Monbukagakusho) 2007 – 2012
Marie Skłodowska-Curie Fellowship (Horizon 2020) 2018 – present
Publications
-
Loss of USP28-mediated BRAF degradation drives resistance to RAF
cancer therapies.
Saei A, Palafox M, Benoukraf T, Kumari N, Jaynes PW, Iyengar PV, Munoz-Couselo E, Nuciforo P, Cortes J, Notzel C, Kumarakulasinghe NB, Richard JLC, Bin Adam Isa ZF, Pang B, Guzman M, Siqin Z, yang H, Tam WL, Serra V, Eichhorn PJA.
Journal of Experimental Medicine (July 2018)
-
The roles of ubiquitin modifying enzymes in neoplastic diseases.
Kumari N, Jaynes PW, Saei A, Iyengar PV, Richard JLC, Eichhorn PJA.
Biochem Biophys Acta Rev Cancer (December 2017)
-
c-Met activation leads to the establishment of a TGFβ-receptor regulatory network in bladder cancer progression.
Sim WJ*, PV Iyengar*, Lama D, Lui Kit Leng S, Ng HC, Gelibter LH, Domany E, Kappei D, Tan TZ, Saie A, Jaynes PW, Verma CS, Kumar AP, Rouanne M, Ha HK, Radulescu C, ten Dijke P, Eichhorn PJA, Thiery JP. * Shared co-first authors
Nature Communications, September 2019
Groups:
